Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion
Harmony Biosciences shares fell 6.4% to $35.82 Tuesday after the company cut its Fragile X program and issued 2026 sales guidance. Harmony forecast Wakix net revenue of $1.0–$1.04 billion for 2026 and confirmed it will phase out ZYN002. Preliminary Wakix revenue for 2025 was about $868 million. CEO Jeffrey Dayno is set to present at the J.P. Morgan Healthcare Conference later Tuesday.
